Terms: = Lymphoma AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
574 results:
1. Splenic B-cell lymphoma/leukemia with prominent nucleoli: A three-case series of the newly named old entity and review of literature.
Rai V; Saha A; Gondha S; Manimaran P; Sawhney J
J Cancer Res Ther; 2024 Jan; 20(1):315-320. PubMed ID: 38554340
[TBL] [Abstract] [Full Text] [Related]
2. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract] [Full Text] [Related]
3. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
4. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
5. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
6. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
7. Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.
Tomkins-Netzer O; Niederer R; Greenwood J; Fabian ID; Serlin Y; Friedman A; Lightman S
Prog Retin Eye Res; 2024 Mar; 99():101245. PubMed ID: 38242492
[TBL] [Abstract] [Full Text] [Related]
8. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
[TBL] [Abstract] [Full Text] [Related]
9. Kinase expression in angiomatoid fibrous histiocytoma: panTRK is commonly expressed in the absence of
Vargas AC; Joy C; Maclean FM; Bonar F; Wong DD; Gill AJ; Cheah AL
J Clin Pathol; 2024 Mar; 77(4):251-254. PubMed ID: 38053271
[TBL] [Abstract] [Full Text] [Related]
10. Management of Brain Metastases: A Review of Novel Therapies.
Bellur S; Khosla AA; Ozair A; Kotecha R; McDermott MW; Ahluwalia MS
Semin Neurol; 2023 Dec; 43(6):845-858. PubMed ID: 38011864
[TBL] [Abstract] [Full Text] [Related]
11. Circulating lung cancer biomarkers: From translational research to clinical practice.
Qian X; Meng QH
Tumour Biol; 2024; 46(s1):S27-S33. PubMed ID: 37927289
[TBL] [Abstract] [Full Text] [Related]
12. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
Fulton-Ward T; Middleton G
Ann Oncol; 2023 Dec; 34(12):1113-1130. PubMed ID: 37875224
[TBL] [Abstract] [Full Text] [Related]
13. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
[TBL] [Abstract] [Full Text] [Related]
14. KZ02 enhances the radiosensitivity of braf-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
15. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi HY; Chang JE
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686423
[TBL] [Abstract] [Full Text] [Related]
16. A prospective evaluation of the diagnostic potential of EBV-DNA in plasma and whole blood.
Ludvigsen LUP; Andersen AS; Hamilton-Dutoit S; Jensen-Fangel S; Bøttger P; Handberg KJ; Ivarsen P; d'Amore F; Bibby BM; Albertsen BK; Jespersen B; Thomsen MK
J Clin Virol; 2023 Oct; 167():105579. PubMed ID: 37683299
[TBL] [Abstract] [Full Text] [Related]
17. Rosai-Dorfman disease of the breast: a clinicoradiologic and pathologic study.
Wang Q; Bradley K; Zhang M; Li S; Li X
Hum Pathol; 2023 Nov; 141():30-42. PubMed ID: 37673345
[TBL] [Abstract] [Full Text] [Related]
18. Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T; Kızmazoglu D; Aktas S; Erol A; Serinan E; Gokbayrak O; Ozdemir SM; Altun Z; Ozer E; Cecen E; Ince D; Olgun N
Front Biosci (Landmark Ed); 2023 Aug; 28(8):171. PubMed ID: 37664946
[TBL] [Abstract] [Full Text] [Related]
19. Higher 13-Gene-Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T-Cell lymphoma Patients.
Chen C; Huang L; Chen Z; Ou Q; Liu S; Jiang X; Chen F; Wei X; Guo H; Shao Y; Zeng C; Li Y; Li W
Adv Biol (Weinh); 2023 Dec; 7(12):e2300042. PubMed ID: 37658484
[TBL] [Abstract] [Full Text] [Related]
20. braf(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.
Yap J; Yuan J; Ng WH; Chen GB; Sim YRM; Goh KC; Teo J; Lim TYH; Goay SM; Teo JHJ; Lao Z; Lam P; Sabapathy K; Hu J
Mol Cancer; 2023 Aug; 22(1):125. PubMed ID: 37543582
[TBL] [Abstract] [Full Text] [Related]
[Next]
